Cite
MLA Citation
C. Harrison et al.. “P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS.” HemaSphere, vol. 6, n.d., pp. 920–921. http://access.bl.uk/ark:/81055/vdc_100159757470.0x000011